Mounjaro is a once-weekly injectable medication developed by Eli Lilly for the treatment of type 2 diabetes. Its active ingredient, tirzepatide, is the first in a new class of medications that targets two gut hormones — GLP-1 and GIP — to improve blood sugar get more info levels and supp